Multiple Ascending Dose Phase 1 Study of ALA-3000
Phase 1
Recruiting
- Conditions
- Treatment Resistant Depression
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Alar Pharmaceuticals Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT06965569
- Locations
- 🇺🇸
Pillar Clinical Research, Little Rock, Arkansas, United States
🇺🇸Arch Clinical Trials, St. Louis, Missouri, United States
🇺🇸Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Single Ascending Dose Study of ALA-1000
Phase 1
Completed
- Conditions
- Opioid-use Disorder
- Interventions
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Alar Pharmaceuticals Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT04122755
- Locations
- 🇺🇸
Innovative Clinical Research, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath